Related Experiment Videos
Augmentin in acute exacerbations of chronic bronchitis
The Journal of International Medical Research
|January 1, 1984
Summary
Augmentin, a combination of amoxicillin and clavulanic acid, effectively treated acute chronic bronchitis in 93% of patients. This antibiotic demonstrated a high cure rate and manageable side effects, making it a valuable option for respiratory infections.
Area of Science:
- Infectious Diseases
- Pharmacology
- Respiratory Medicine
Background:
- Acute chronic bronchitis is a common lower respiratory tract infection.
- Bacterial resistance, including beta-lactamase production, poses a challenge in treatment.
- Amoxicillin combined with clavulanic acid (Augmentin) offers a broad spectrum of activity.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of Augmentin in treating acute chronic bronchitis.
- To assess the bacteriological response to Augmentin therapy.
- To determine the utility of parenteral Augmentin in lower respiratory tract infections.
Main Methods:
- A study involving 45 patients with acute chronic bronchitis.
- Initial parenteral administration of Augmentin followed by oral treatment for a mean of 7.1 days.
- Clinical and bacteriological evaluations, including sputum sample analysis.
Main Results:
- An overall clinical cure rate of 93% was achieved.
- Bacteriological eradication of initially isolated organisms occurred in 91% of cases.
- Side effects were comparable to other amoxicillin therapies.
Conclusions:
- Parenteral Augmentin is a valuable addition to the treatment of lower respiratory tract infections.
- Augmentin demonstrates high efficacy and a favorable safety profile for acute chronic bronchitis.
- The study highlights the importance of considering beta-lactamase-producing organisms in treatment selection.